What is Octostatin?
It is used in the treatment of secretory VIP(Vasoactive Intetinal Peptide ) and acromegaline carcinoid tumors.
Actrotide mimics the effects of the natural hormone somatostatin (somatostatin). It is more potent in inhibiting the secretion of growth hormone glucagon and insulin than somatostatin and has a longer effect. Like somatostatin, it inhibits the secretion of serotonin, pancreatic peptides, gastrin, secretin, intestinal peptides, and motilin.
Injections for symptomatic treatment of patients with metastatic carcinoid tumors have been shown to suppress or inhibit severe diarrhea and disease-related hot flashes.
- Taking this medicine in patients with diabetes may reduce the need for insulin or a blood sugar-lowering drug.
- It inhibits gallbladder movements and bile flow.
- Monitor the patient’s liver and thyroid function in long-term use. The patient’s liver, gallbladder and thyroid status should be evaluated before use and at intervals of 6-12 months of treatment with this drug.
Octostatin Side Effects
Pain and irritation at the injection site and impaired hyperglycemia after eating are common side effects of this drug.
Octostatin Drug Interactions
Concomitant use of octreotide with insulin and hypoglycemic drugs in diabetics reduces the need for these drugs.
Octreotide reduces its plasma concentration by reducing the absorption of cyclosporine.
Octostatin Recommended tips
- Thyroid function should be monitored during long-term use of Indaro.
- The condition of the gallbladder should be evaluated before use and at intervals of 6-12 months of treatment with this drug.
- Abrupt discontinuation of the drug may cause the gallbladder to constrict, leading to biliary colitis and pancreatitis.
- It should be changed constantly to prevent irritation and pain at the injection site.
- Gastrointestinal side effects may be reduced if the drug is injected between meals or at bedtime.
In carcinoid, glucagon-secreting, and VIP-secreting tumors, 50 micrograms are first injected 1 to 2 times a day by subcutaneous injection, which gradually increases to 200 micrograms 3 times a day, depending on the response. In carcinoid tumors, the drug should be discontinued if the drug does not work after one week. In acrogalia for short-term treatment before pituitary surgery or for long-term treatment in patients who have not responded to other treatments or until radiation therapy is fully effective, by subcutaneous injection of 200-100 micrograms 3 The battery is consumed daily, if there is no improvement with these values for up to 3 months, the drug should be discontinued.
Was this helpful?
0 / 0